AbstractA variety of experiments have thus far shown cyclosporine to be not nearly as successful in preventing rejection of pancreas allografts (islets, fetal, vascularized segmental) in experimental animals as it is with other tissues. Clinical experience has also been relatively disappointing, although surgeons at most centers have the impression that it is marginally better than azathioprine and steroids. The role of cyclosporine in pancreas transplantation, and indeed the place of pancreas transplantation, remains uncertain at this time.